Drug intelligence / Profile preview

favipiravir + baloxavir

Development stage: Unknown
Lead developer: FUJIFILM Toyama Chemical
Modality: Small Molecules
Administration: Oral

Overview

A combination of two distinct antiviral medications that target different aspects of the influenza virus replication cycle. Favipiravir inhibits RNA-dependent RNA polymerase (RdRp) by acting as a nucleoside analog that terminates RNA strand elongation, preventing viral genome replication. Baloxavir marboxil is a prodrug that is metabolized to baloxavir acid, which inhibits the cap-dependent endonuclease function of the polymerase acidic (PA) protein, preventing viral mRNA synthesis. Both drugs are effective against influenza A and B viruses, with favipiravir also showing activity against influenza C and D viruses.

Brand names: Xofluza
Other names: FavilavirFapilavirT705T-705T 705S-033188S033188S 033188

Targets

CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)Influenza A virus RNA-directed RNA polymerase complex

Beyond the preview

Go deeper on favipiravir + baloxavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on favipiravir + baloxavir.

Explore the full profile